← All trials
NCT02148445
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2014
- Primary completion
- Dec 31, 2016
- Completion date
- Dec 31, 2016
- First posted
- May 28, 2014
- Last posted
- Oct 6, 2017
- Enrollment
- 398
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of KansasLead sponsor
- Patient-Centered Outcomes Research InstituteCollaborator
- University of KansasOverall official - principal investigator
- University of KansasReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.